Evidence map›Paper›PMID 41327396›Full record

ArticleThyroid research2025

Papillary thyroid carcinoma: morphological features and association with normalized BRAFV600E allelic frequency; clonality and morphology investigating mutations through microscopy.

Maria Soledad Martínez-Martin, María Eugenia Galán-García, Eduardo José Araujo-Ruano, Eduardo Salido-Ruiz, Mauro Boronat, Pedro Saavedra-Santana, Carlota Recio, Juan José Cabrera-Galván

Abstract read
In one paragraph

Article in Thyroid research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maria Soledad Martínez-MartinPathology Unit, Faculty of Medicine, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
María Eugenia Galán-GarcíaPathological Anatomy Service, Maternal and Insular Hospital Complex of the Canary Health Service, Las Palmas de Gran Canaria, Spain.
Eduardo José Araujo-RuanoPathology Unit, Faculty of Medicine, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Eduardo Salido-RuizPathology Unit, Faculty of Medicine, University of La Laguna, Santa Cruz de Tenerife, Spain.
Mauro BoronatSection of Endocrinology and Nutrition, Maternal and Insular Hospital Complex of the Canary Health Service, Las Palmas de Gran Canaria, Spain.
Pedro Saavedra-SantanaMathematics Department, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Carlota RecioInstituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Farmacología Molecular y Traslacional, Universidad de Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain.
Juan José Cabrera-GalvánPathology Unit, Faculty of Medicine, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain. juanjose.cabrera@ulpgc.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPapillary thyroid carcinoma (PTC) is the most common endocrine malignancy. The BRAF V600E (c·1799T > A; p.Val600Glu) mutation results in oncogenic activation of the MAP-kinase pathway and plays a key role in the development and aggressiveness of PTC. Significant morphological differences have been observed between BRAF V600E-mutated and non-mutated PTCs. The BRAF V600E mutation has been associated with adverse clinicopathological features, including lymph node metastasis, recurrence, tumor size, extrathyroidal invasion, and unfavorable outcomes, particularly when the mutant allele fraction is high. However, the relationship between the proportion of mutated neoplastic cells and the morphological characteristics of PTC remains unclear. This study aims to investigate the potential connection between the proportion of mutated neoplastic tumor cells and the morphological characteristics of PTC, and to evaluate the impact of normalizing the allele frequency to the percentage of neoplastic tumor cells in the tissue used for DNA extraction.

methodsEighty-five cases of PTC, spanning a 12-year period, were analysed with a focus on specific morphological features, including infiltrative tumor margin, plumps pink cells, desmoplasia and tumor size. Additional features included surgical margin status, lymph node and distant metastasis, multifocality, psammoma bodies, fibrosis, encapsulation and nuclear atypia. DNA mutation analysis was performed using pyrosequencing, and the percentage of neoplastic cells (MNC) was estimated from the slide used for DNA extraction. Normalization of the allele frequency was performed using a corresponding formula. Tumors were classified into three groups: subclonal ( < 30% MNC), heterogeneous (30-80%) and clonal ( > 80%). Statistical analysis, including interquartile range (IQR) calculations, was conducted.

resultsThe frequency of mutated cases (BRAF V600E ≥10%) was 57 out of 85 cases (67%). The variables infiltrative tumor margins (p < 0.001), plump pink cells (p = 0.007), and desmoplasia (p = 0.002) showed statistically significant associations with clonality, with the first remaining independently significant in the multivariate logistic regression analysis (p < 0.001). Surgical margin status, distant metastasis, and tumor size also showed significance. Similar results were obtained using IQR analysis for the first three variables and for surgical margin status. The remaining variables did not reach statistical significance.

conclusionsThe presence of infiltrative tumor margin, plump pink cells, and myxoid desmoplasia, may serve as active markers associated with the normalized BRAF V600E mutation. These findings suggest that the mutation acts as a driver in both early and late stages of PTC development. Furthermore, a direct relationship between tumor size and clonality underscores the role of BRAF V600E mutation in tumor progression and morphological evolution.

Indexed as

BRAF V600E mutationMorphologyPapillary thyroid carcinoma

Identifiers

PMID41327396
PMCPMC12670734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.